Skip to main content

Table 2 Overview of studies for dyslipidemia included in the final analysis (N = 11)

From: A semi-systematic review on hypertension and dyslipidemia care in Egypt—highlighting evidence gaps and recommendations for better patient outcomes

Search type Study: first author; publication date Brief study design Sample size (N); characteristics Prevalence Awareness Screening Diagnosis Treatment Adherence Control Remarks
Data as per the MAPS inclusion criteria
Unstructured Ministry of Health & population, Egypt Preventive Sector Central Epidemiology and Disease Surveillance (ESU) Non-Communicable Disease Surveillance Unit (NCDSU); 2006 National cross-sectional survey N = 9780; participants (15–65 years) 19.4% x x x x x x NA
WHO and ARE-Ministry of Health & Population: Egypt National STEPwise Survey of Non-Communicable Diseases Risk Factors 2011-2012; 2012 Multistage cluster sample design N = 5300; participants (15–65 years) 36.8% x x x x x x NA
Supplementary Record Egypt National STEPwise Survey For Noncommunicable Diseases Risk Factors Report; 2017 National cross-sectional community-based household survey N = 6680; nationally representative sample of Egyptian adults (15–69 years). 19.2% x 8.6% x x x x NA
Data deviates from the MAPS inclusion criteria (definitions/special patient subgroups)
Structured The DYSlipidemia International Study (DYSIS)-Egypt: A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment: El Etriby A; 2013 Cross-sectional, observational, multinational study N = 1458; patients (≥ 45 years) on stable statin treatment. x x x x x x 33.7% Control data extracted based on target LDL-C attainment
Lipid profile in Egyptian patients with coronary artery disease: Ibrahim MM; 2013 Retrospective consecutive sampling of patients with CAD N = 1000; patients ranged from 19 to 90 years. 58.7% x x x x x x Data extracted from patients with stable CAD or had a history MI
Centralized Pan-Middle East Survey on the Under- Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt: Reda A; 2014 Multicenter, observational study N = 1043; subjects (≥ 18 years) were receiving lipid-lowering drug treatment. x 76.0% x x x x 32.5% Control data extracted based on target LDL-C attainment
Comparative study between elderly and younger patients with acute coronary syndrome: Obaya M; 2015 Comparative study between elderly and younger patients with ACS N = 570; patients were divided into 2 groups: elderly ≥ 60 years; younger < 60 years. 50.9 x x x x x x Data extracted from younger patients (< 60 year) presenting with ACS; dyslipidemia not defined
Centralized Pan-Middle East Survey on the Under- Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt: Reda A; 2017 Observational, multicenter, cross-sectional survey N = 896; Subjects (≥ 18 years) receiving lipid-lowering drug treatment. x 75.0% x x x 59.0% 34.4% Data extracted based on LDL-C levels
Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome: Sobhy M; 2018 Prospective, observational study of patients presenting with ACS N = 199; patients (≥ 18 years) who were hospitalized for ACS and receiving lipid-lowering treatment. x x x x 73.9% x 5.1% (very high risk; < 70 mg/dL)
27.3% (high risk; < 100 mg/dL)
32. 3% (moderate risk; < 115 mg/dL)
14.3% (low risk; < 130 mg/dL)
Data extracted on investigating selected subpopulations (ACS patients); control data extracted based on target LDL-C attainment corresponding to different risk categories
The pattern of risk-factor profile in Egyptian patients with acute coronary syndrome: phase II of the Egyptian cross-sectional CardioRisk project: Reda A; 2019 Multi-center, observational, cross-sectional study of patients presenting with ACS N = 1681; participants (≥18 years) having a history of lipid-lowering therapy or LDL-C > 70 mg/dL (>  1.81 mmol/L). 52.50% x x x x x x Data extracted on investigating ACS patients; dyslipidemia definition is based on LDL-C levels
Registry of the Egyptian specialized hypertension clinics: patient risk profiles and geographical differences: El Faramawy A; 2019 Nationwide Specialized Hypertension Clinics Registry N = 4701; dyslipidemia considered when LDL ≥ 130 mg/dL, HDL ≤ 50 mg/dL in women and ≤ 40 mg/dL in men, and TG ≥150 mg/dL or if the patient was receiving a lipid-lowering agent 8.90% x x x x x x Data extracted on investigating hypertensive patients based on LDL-C, HDL, and TG levels
  1. ACS, acute coronary syndrome; HDL, high-density lipoprotein; CAD, coronary artery disease; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable; TG, triglycerides